Asia-Pacific dengue virus diagnostic test Market Research - 2035
The Asia-Pacific dengue virus diagnostic test market size was valued at $ 53.25 million in 2023 and is projected to reach $ 99.45 million by 2035, registering a CAGR of 5.3% from 2024 to 2035.
The growth of the Asia-Pacific dengue virus diagnostic test market is driven by rise in prevalence of dengue fever cases. For instance, according to the World Health Organization (WHO) Southeast Asia region, by November 2023, Bangladesh reported 308,167 cases, a sharp rise from 62,382 in 2022. Thailand also saw a drastic increase, with dengue cases jumping over 300%, from 46,678 in 2022 to 136,655 in 2023.
Dengue is a viral infection transmitted primarily by Aedes mosquitoes, causing symptoms such as high fever, severe headache, pain behind the eyes, joint and muscle pain, and rash. In some cases, it can progress to severe dengue (also known as dengue hemorrhagic fever or dengue shock syndrome), which can be life-threatening. Dengue virus testing is crucial for accurate diagnosis and management. Common methods include polymerase chain reaction (PCR) to detect viral RNA and enzyme-linked immunosorbent assay (ELISA) to identify antibodies against the virus. Early detection helps differentiate dengue from other similar illnesses, guiding appropriate treatment and preventing complications, especially in endemic areas with frequent outbreaks of the disease.
Key Takeaways
- On the basis of test type, the ELISA-based Tests segment dominated the market in 2023. However, the RT-PCR based Tests segment is anticipated to grow at the highest CAGR during the forecast period.
- On the basis of mode of testing, the laboratory-based testing segment dominated the market in 2023. However, the point-of-care testing segment is anticipated to grow at the highest CAGR during the forecast period.
- On the basis of end user, the diagnostic centers segment dominated the market in 2023 and is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, SR1 generated the largest revenue in 2023 and is anticipated to grow at the highest CAGR during the forecast period.
Market Dynamics
The Asia-Pacific dengue virus diagnostic test market is witnessing significant growth due to a combination of rising disease prevalence, government initiatives, and advancements in diagnostic testing technologies. The region, with its tropical climate and densely populated areas, has become a hotspot for dengue outbreaks, which are escalating the demand for effective diagnostic solutions. According to the World Health Organization's Global Dengue Surveillance 2024 data, reported dengue cases surged alarmingly from 27,675 in July 2024 to 51,183 in October 2024, underlining the urgency for reliable diagnostic testing to curb the disease's impact.
Government initiatives across the region drive the market growth. Countries like India have implemented comprehensive guidelines to improve early detection, accurate diagnosis, and disease management. The National Center for Vector Borne Diseases Control (NCVBDC) in India introduced the National Guidelines for Clinical Management of Dengue Fever 2023. These guidelines highlight the importance of laboratory diagnostic tests, including serological tests like the NS1 antigen test and IgM/IgG antibody tests, as well as PCR testing. PCR tests, in particular, are emphasized for their ability to identify the dengue virus during the acute phase, aiding in early detection. The guidelines also advocate for standardized testing protocols, timely sample collection, and thorough clinical assessments to ensure accurate diagnoses and timely treatments.
In addition to national efforts, global organizations like the World Health Organization (WHO) play a crucial role in enhancing the quality and availability of diagnostic products in the Asia-Pacific region. The WHO actively invites manufacturers of dengue diagnostic products to submit expressions of interest for evaluation by the WHO Expert Review Panel for Diagnostic Products (ERPD). This initiative ensures that diagnostic kits meet stringent standards for quality, safety, and performance. Eligible products include rapid diagnostic tests (RDTs), enzyme-linked immunosorbent assays (ELISAs), and nucleic acid amplification tests (NAATs). Manufacturers are required to provide comprehensive documentation, such as product dossiers, performance data, and evidence of compliance with international quality standards. Through this initiative, the WHO aims to enhance access to quality-assured diagnostic kits in endemic regions, supporting effective disease control and management.
The Asia-Pacific region’s governments and healthcare organizations are also investing in awareness programs to educate the public about the importance of early testing and prevention strategies. Public health campaigns stress the value of timely medical attention and the availability of advanced diagnostic tools, helping to drive the adoption of laboratory-based testing and point-of-care diagnostic solutions. For instance, initiatives to provide free or subsidized diagnostic services in rural and underserved areas have further improved access to dengue virus testing.
The market’s growth is further bolstered by technological advancements in diagnostic tools. Modern ELISA-based tests and RT-PCR-based tests are gaining popularity due to their accuracy and ability to provide quick results. ELISA tests are particularly preferred for detecting dengue-specific antibodies, while RT-PCR tests are used for identifying the virus during the early stages of infection. These advancements ensure higher accuracy and reliability in diagnostic results, enabling healthcare providers to initiate timely and appropriate treatment protocols.
Moreover, the rising involvement of private diagnostic companies in research and development has expanded the availability of advanced diagnostic kits. Partnerships between governments, non-governmental organizations, and private players are fostering innovation in dengue diagnostics, making high-quality testing solutions more accessible across the region. This collaborative approach is helping to address the rising disease burden effectively.
However, the factor that hinder the Asia-Pacific dengue virus diagnostic test market growth is the limited healthcare infrastructure in rural and underserved areas. These regions often lack access to advanced diagnostic tools and skilled personnel, which hampers early detection and timely treatment of dengue fever. Additionally, the high cost of advanced diagnostic tests, such as RT-PCR, poses affordability challenges for low-income populations, limiting market penetration. Moreover, the lack of standardized testing protocols across some countries in the region further complicates accurate and consistent diagnosis, potentially affecting patient outcomes.
Furthermore, an opportunity lies in the growing adoption of point-of-care (POC) diagnostic solutions. These portable and cost-effective testing devices enable rapid diagnosis in remote and resource-constrained settings, bridging the gap in healthcare access. Government initiatives and funding to promote POC testing in rural areas, coupled with advancements in technology, are expected to drive market growth. Additionally, partnerships between private diagnostic companies and public health organizations to develop affordable, high-quality diagnostic kits present a lucrative avenue for expansion in the region
Segmental Overview
The Asia-Pacific dengue virus testing market is segmented on the basis of test type, mode of testing, end user, and country. On the basis of test type, it is segmented into ELISA-based tests, RT-PCR based tests, and others. The ELISA-based tests segment is further classified into IgG and IgM, and nonstructural protein 1 (NS1). By mode of testing, it is bifurcated into laboratory-based testing, and point-of-care testing. By end user, it is segregated into hospitals, diagnostic centers, and others. Country wise, the market is analyzed across China, SR1, SR2, SR3, and Japan. The SR1 is segmented into Indonesia, India, Philippines, Pakistan, Myanmar. The SR2 is segmented into Thailand, Viet Nam, Malaysia, and Taiwan. The SR3 is segmented into Australia, South Korea, Singapore, New Zealand, and Hong Kong.
By Test Type
The ELISA-based tests segment held the largest Asia-Pacific dengue virus diagnostic test market share in 2023 owing to their high accuracy, reliability, and widespread adoption in laboratory settings. These tests are preferred for detecting dengue virus antibodies and antigens, enabling early and precise diagnosis. Additionally, advancements in ELISA technologies and increased government initiatives to strengthen healthcare infrastructure contributed significantly to the segment's market share.
However, RT-PCR based tests is expected to register the highest CAGR during the forecast period owing to their superior sensitivity and specificity in detecting dengue virus at early stages. These tests are highly effective in identifying viral RNA, making them essential for accurate and rapid diagnosis. The increasing adoption of molecular diagnostic techniques, advancements in RT-PCR technology, and growing awareness about early dengue detection are key factors driving their projected growth.
By Test Type
ELISA based tests segment held a dominant position in the market in 2023.However, RT-PCR based tests is anticipated to grow at a fastest rate during the forecast period.
By Mode of testing
The Laboratory testing segment held the largest Asia-Pacific dengue virus diagnostic test market share in 2023 owing to its high accuracy and reliability in diagnosing dengue infections. Equipped with advanced technologies like ELISA and RT-PCR, laboratories provide comprehensive diagnostic solutions. Additionally, increased healthcare infrastructure and the rising prevalence of dengue in the region have boosted demand for laboratory-based testing services.
However, point of care testing is expected to register the highest CAGR during the forecast period owing to its rapid results, ease of use, and suitability for remote or resource-limited settings. The growing demand for decentralized healthcare solutions, coupled with advancements in portable diagnostic technologies, further drives the adoption of point-of-care testing for dengue diagnosis.
By Mode Of Testing
Laboratory based testing segment held a dominant position in the market in 2023. However, Point of care testing is anticipated to grow at a fastest rate during the forecast period.
By End User
The diagnostic centers segment held the largest Asia-Pacific dengue virus diagnostic test market share in 2023 and is expected to register the highest CAGR during the forecast period, owing to the availability of advanced testing facilities, skilled professionals, and comprehensive diagnostic services. Increased patient preference for accurate, reliable results and the rising prevalence of dengue further fuel this segment's growth.
By End User
Diagnostic Centers segment held a dominant position in the market in 2023 and is anticipated to grow at a fastest rate during the forecast period.
By Region
The Asia-Pacific dengue virus diagnostic test market is analyzed across China, SR1, SR2, SR3, and Japan. The SR1 accounted for a major share of the Asia-Pacific dengue virus diagnostic test market in 2023 and is expected to maintain its dominance during the forecast period. This is attributed to the high prevalence of dengue fever in these countries, increasing government initiatives for disease control, and the growing availability of advanced diagnostic tools. Rising public awareness and improved healthcare infrastructure also contribute to the region's significant market position.
Competition Analysis
Competitive analysis and profiles of the major players in the Asia-Pacific dengue virus diagnostic test market include OriGene Technologies, Inc., Abbott Laboratories, InBios International, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Mylab Discovery Solutions Pvt. Ltd., Trivitron Healthcare, SD Biosensor, INC., Bio-Rad Laboratories, Inc., and BIOMERIEUX. Key players operating in the market have adopted various strategies such as product launch and acquisition as their key strategy to expand their product portfolio.
Recent Developments in Asia-Pacific dengue virus diagnostic test Industry
- In September 2023, Mylab Discovery Solutions Pvt. Ltd. introduced a range of Dry Luminescence Immunoassay-based tests, including Dengue IgG/IgM tests, which offer faster, more reliable results. These innovations contribute to the growing demand for rapid diagnostic kits, which help in early-stage detection, critical for controlling the spread of dengue.
- In June 2023, Fujifilm (Thailand) Ltd., announced that it continues its unwavering commitment to never stop innovating to tackle social issues and contribute to a sustainable and healthier world. In line with its vision, the company recently unveiled a groundbreaking high-sensitivity dengue detection kit featuring Silver Amplification technology.
Analyst Review
This section provides various opinions of top-level CXOs in the Asia-Pacific dengue virus diagnostic test market. According to the insights of CXOs, the market for dengue diagnostics is poised for significant growth, driven by increasing prevalence, awareness of the disease and advancements in diagnostic technologies. CXOs emphasized that while the region’s healthcare infrastructure is improving, there is still a need for greater accessibility to affordable and rapid diagnostic solutions. They noted that innovation in point-of-care diagnostics and molecular testing technologies is crucial for addressing the evolving challenges in disease detection.
CXOs further added that regulatory hurdles and economic constraints in some regions could slow the widespread adoption of advanced diagnostic tools. The market, however, presents ample opportunities for growth, particularly through strategic partnerships and collaborations that can enhance distribution channels and streamline regulatory processes. Furthermore, investment in public health awareness campaigns and diagnostic infrastructure is vital to drive demand for testing and ultimately reduce the burden of dengue in the region.
The total market value of North America Stroke Management monitoring market is $53.24 million in 2023.
The market value of Asia-Pacific dengue virus diagnostic tests Market in 2035 is $99.63 million.
The forecast period for Asia-Pacific dengue virus diagnostic tests Market is 2024 to 2035.
The base year is 2023 in Asia-Pacific dengue virus diagnostic tests Market.
Dengue virus testing identifies the virus or antibodies in the blood to confirm infection. Common methods include polymerase chain reaction (PCR) to detect viral RNA and enzyme-linked immunosorbent assay (ELISA) to identify antibodies. Early diagnosis is crucial for timely treatment.
Loading Table Of Content...
